BioCentury | Dec 11, 2020
Finance

AbCellera valuation tops $15B as 2020’s IPO class nears completion

...a market cap of $6 billion, while the 76% gain for gene therapy play 4D Molecular Therapeutics Inc....
...postmoney valuation of HK$9.5 billion.Staff Writer Hongjiang Li contributed to this report. Paul Bonanos AbCellera Biologics Inc. 4D Molecular Therapeutics Inc. Certara...
BioCentury | Dec 5, 2020
Management Tracks

CureVac hires GSK Vaccines veteran Blanc as CBO and chief commercial officer; plus moves at Spero, 4D, Transgene, Achilles and Datavant

...NASDAQ:SPRO) as chief legal officer. She was general counsel at Millendo Therapeutics Inc. (NASDAQ:MLND).Gene therapy play 4D Molecular Therapeutics Inc....
...was VP of sales, technology solutions at IQVia Holdings Inc. (NYSE:IQV). Danielle Golovin CureVac N.V. Spero Therapeutics Inc. 4D Molecular Therapeutics Inc. Transgene...
BioCentury | Dec 2, 2020
Finance

Data Byte: IPO queue picks up post-election

...with Eli Lilly and Co. (NYSE:LLY), on Nov. 9 to treat COVID-19 outpatients. Gene therapy company 4D Molecular Therapeutics Inc....
BioCentury | Nov 25, 2020
Emerging Company Profile

Building Resilience into U.S. biomanufacturing

...Raymond G. Perelmen Center for Cellular and Molecular Therapeutics...
BioCentury | Jul 24, 2020
Finance

Four more biotech IPOs reach the market, but no big first-day pop in the bunch

...hemorrhagic cystitis, is due to enter a pivotal study next quarter. Also this week, 4D Molecular Therapeutics Inc....
...ENPP1 - Ectonucleotide pyrophosphatase/phosphodiesterase 1 Paul Bonanos, Associate Editor Annexon Inc. iTeos Therapeutics S.A. Nurix Therapeutics Inc. Inozyme Pharma Inc. 4D Molecular Therapeutics Inc. AlloVir iTeos...
BioCentury | Jun 27, 2020
Deals

Who’ll buy uniQure now?

...$1 million. Only one patient, in Germany, was ever reimbursed. UniQure’s roots lie in Amsterdam Molecular Therapeutics...
BioCentury | Jun 17, 2020
Finance

Crossovers pile into new rounds for C4, 4D Molecular

...provided $20 million in venture debt funding alongside the series B round’s equity component. 4D Molecular Therapeutics...
...CF program, 4D-710. Meredith Durkin Wolfe contributed to this report. Paul Bonanos, Associate Editor C4 Therapeutics Inc. 4D Molecular Therapeutics Inc. Perceptive...
BioCentury | Jan 18, 2020
Product Development

Mapping the path to gene therapy 2.0

...Therapeutics Inc. (NASDAQ:SRPT) to use the capsid technology in CNS and neuromuscular disease programs. 4D Molecular Therapeutics...
BioCentury | Dec 4, 2019
Company News

Audentes takeout signals pharma's continued interest in gene therapy manufacturing

...MeiraGTx to develop gene therapies for ophthalmic indications; AZ's MedImmune Inc. unit partnered with 4D Molecular Therapeutics Inc....
BioCentury | Nov 22, 2019
Financial News

Follow-on roundup: Karuna, CRISPR, Molecular Therapeutics, OptiNose

...Since market close on Wednesday, Karuna, CRISPR Therapeutics, Molecular Therapeutics and OptiNose have raised an aggregate of...
Items per page:
1 - 10 of 184
BioCentury | Dec 11, 2020
Finance

AbCellera valuation tops $15B as 2020’s IPO class nears completion

...a market cap of $6 billion, while the 76% gain for gene therapy play 4D Molecular Therapeutics Inc....
...postmoney valuation of HK$9.5 billion.Staff Writer Hongjiang Li contributed to this report. Paul Bonanos AbCellera Biologics Inc. 4D Molecular Therapeutics Inc. Certara...
BioCentury | Dec 5, 2020
Management Tracks

CureVac hires GSK Vaccines veteran Blanc as CBO and chief commercial officer; plus moves at Spero, 4D, Transgene, Achilles and Datavant

...NASDAQ:SPRO) as chief legal officer. She was general counsel at Millendo Therapeutics Inc. (NASDAQ:MLND).Gene therapy play 4D Molecular Therapeutics Inc....
...was VP of sales, technology solutions at IQVia Holdings Inc. (NYSE:IQV). Danielle Golovin CureVac N.V. Spero Therapeutics Inc. 4D Molecular Therapeutics Inc. Transgene...
BioCentury | Dec 2, 2020
Finance

Data Byte: IPO queue picks up post-election

...with Eli Lilly and Co. (NYSE:LLY), on Nov. 9 to treat COVID-19 outpatients. Gene therapy company 4D Molecular Therapeutics Inc....
BioCentury | Nov 25, 2020
Emerging Company Profile

Building Resilience into U.S. biomanufacturing

...Raymond G. Perelmen Center for Cellular and Molecular Therapeutics...
BioCentury | Jul 24, 2020
Finance

Four more biotech IPOs reach the market, but no big first-day pop in the bunch

...hemorrhagic cystitis, is due to enter a pivotal study next quarter. Also this week, 4D Molecular Therapeutics Inc....
...ENPP1 - Ectonucleotide pyrophosphatase/phosphodiesterase 1 Paul Bonanos, Associate Editor Annexon Inc. iTeos Therapeutics S.A. Nurix Therapeutics Inc. Inozyme Pharma Inc. 4D Molecular Therapeutics Inc. AlloVir iTeos...
BioCentury | Jun 27, 2020
Deals

Who’ll buy uniQure now?

...$1 million. Only one patient, in Germany, was ever reimbursed. UniQure’s roots lie in Amsterdam Molecular Therapeutics...
BioCentury | Jun 17, 2020
Finance

Crossovers pile into new rounds for C4, 4D Molecular

...provided $20 million in venture debt funding alongside the series B round’s equity component. 4D Molecular Therapeutics...
...CF program, 4D-710. Meredith Durkin Wolfe contributed to this report. Paul Bonanos, Associate Editor C4 Therapeutics Inc. 4D Molecular Therapeutics Inc. Perceptive...
BioCentury | Jan 18, 2020
Product Development

Mapping the path to gene therapy 2.0

...Therapeutics Inc. (NASDAQ:SRPT) to use the capsid technology in CNS and neuromuscular disease programs. 4D Molecular Therapeutics...
BioCentury | Dec 4, 2019
Company News

Audentes takeout signals pharma's continued interest in gene therapy manufacturing

...MeiraGTx to develop gene therapies for ophthalmic indications; AZ's MedImmune Inc. unit partnered with 4D Molecular Therapeutics Inc....
BioCentury | Nov 22, 2019
Financial News

Follow-on roundup: Karuna, CRISPR, Molecular Therapeutics, OptiNose

...Since market close on Wednesday, Karuna, CRISPR Therapeutics, Molecular Therapeutics and OptiNose have raised an aggregate of...
Items per page:
1 - 10 of 184